The complete list of business models in the cell therapy market

Download our beautiful pitch about the cell therapy market

A quick summary table

Metric	Value
Number of distinct business models mapped	24
Average scalability score across cell therapy models	6.5 / 10
Models scoring 8 or higher on scalability	6 of 24 (25%)
Models scoring 8 or higher on margin potential	8 of 24 (33%)
Models scoring 8 or higher on defensibility	12 of 24 (50%)
Dominant revenue model in cell therapy	Outcome-based (19 of 24 models)
Most common sales motion	Specialist enterprise sales
Capital intensity profile	High in 17 of 24 models
Models with licensing or BD-led revenue	5 of 24
Best scalability category	In vivo engineering and platform licensing
Largest TAM expansion opportunity	Autoimmune and immune tolerance models
Primary disease focus anchoring pricing	Oncology (hematologic and solid tumors)

All the business models in the cell therapy market

Here is a table that maps the main business models in the cell therapy market, highlighting how they differ in scalability, margins, defensibility, capital intensity, and monetization approach.

Key insights about business models in the cell therapy market

A few words about our methodology

This table maps the main business models used by startups in the cell therapy market.

To build it, we first analyzed the leading cell therapy companies and examined how they actually generate revenue, from CAR-T commercializers and allogeneic manufacturers to platform licensors and in vivo delivery developers.

We then grouped similar approaches into clear business model categories. The goal was to capture meaningful differences without creating an overwhelming number of models.

Each business model is evaluated across four structural dimensions: scalability, margin potential, defensibility, and capital intensity.

Scalability measures how easily the model can grow without proportional increases in cost. Margin potential reflects the long-term gross margin typically achievable once the model reaches maturity.

Defensibility captures how sustainable the competitive advantage can be over time, considering factors like switching costs, manufacturing know-how, regulatory experience, or proprietary cell engineering IP.

Capital intensity indicates how much upfront investment is usually required to build and scale the model.

For scalability, margin potential, and defensibility, scores range from 0 to 10. Lower scores indicate structural limitations, while scores above 7 generally signal strong economic potential.

These scores are not precise forecasts. They reflect the typical economics we observe across cell therapy companies using that model.

This framework is part of the broader research behind our report covering the cell therapy market, where we analyze the ecosystem in much more detail.

If you want to better understand the ecosystem, you can also check our ranking of startups with the most fundraising in the cell therapy market and the list of the startups with the biggest valuations in the cell therapy market.

If you want more detail about our business model analysis or about a specific company in the cell therapy market, feel free to contact us. We will gladly explain.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.

How we created this content 🔎📝

At New Market Pitch, we kept seeing the same problem: when you look at a new market, the data is either missing, paywalled, or buried in 300-page reports that feel like they were written in the 80s. On the other side, LLMs and random blog posts give you confident answers with no sources, and sometimes they just make things up. That’s not good enough when you’re about to invest real money or launch a company.

So we decided to fix the experience. For each market we cover, we build a structured database and update it on a regular basis. We track funding rounds, fund memos, M&A moves, partnerships, new products, policy changes, and the real activity of startups and incumbents. Then we turn all of that into a clear “market pitch” that shows where the opportunities are and how people actually win in that space.

Every key data point is checked, sourced, and put back into context by our team. That’s how we can give you both speed and reliability: fast coverage of new markets, without the usual guesswork.